"Der Einfluß von Batimastat auf Prostatakarzinom Zellinien und den Dunning Tumor der Ratte"Dietmar Borchert111.11.21.2.121.2.231.2.31.2.4451.2.51.361.3.1781.3.291.3.310111.41.4.1121.4.2131.4.3141.4.41.5151.5.11.5.2161.61.6.1171.6.218585#3491.6.3191.71.7.1201.7.221221.7.3232243253.13.23.33.4263.53.6273.7284294.1438#29830439#29231439#28732439#2874.233429#2893435604#65236604#662373839448#28740414.342517#35343516#31944524#3195455.1465.247485.3495.3.15051525.4535.4.154555.4.2565.4.357585.4.4595.4.56061625.4.66364AbkürzungsverzeichnisVI Literaturverzeichnis65 Anhang96269#28997Danksagung98Lebenslauf99Eidestattliche ErklärungdeInhaltsverzeichnisHilfe Literaturverzeichnis

[1] Pienta, K. J. und Esper, P. S. (1993): Risk factors for prostate cancer, Ann.Intern.Med. 118 [10], Seite 793-803. [2] Robert - Koch - Institut:Tumorregister.URL: www.rki.de/GBE/KREBS/KREBS.HTM?/GBE/KREBS/SCHAETZUNG/KREBSNEUERKRANKUNGEN1998.HTM&1 [3] Jemal, A.; Tiwari, R. C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E. J. und Thun, M. J. (2004): Cancer statistics, 2004, CA Cancer J Clin. 54 [1], Seite 8-29. [4] Hankey, B. F.; Feuer, E. J.; Clegg, L. X.; Hayes, R. B.; Legler, J. M.; Prorok, P. C.; Ries, L. A.; Merrill, R. M. und Kaplan, R. S. (1999): Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates, J Natl.Cancer Inst. 91 [12], Seite 1017-1024. [5] Chybowski, F. M.; Keller, J. J.; Bergstralh, E. J. und Oesterling, J. E. (1991): Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters, J Urol. 145 [2], Seite 313-318. [6] Smith, D. S. und Catalona, W. J. (1994): The nature of prostate cancer detected through prostate specific antigen based screening, J Urol. 152 [5 Pt 2], Seite 1732-1736. [7] Harlan, L.; Brawley, O.; Pommerenke, F.; Wali, P. und Kramer, B. (1995): Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate, J Clin.Oncol. 13 [1], Seite 93-100. [8] Johansson, J. E.; Adami, H. O.; Andersson, S. O.; Bergstrom, R.; Krusemo, U. B. und Kraaz, W. (1989): Natural history of localised prostatic cancer. A population-based study in 223 untreated patients, Lancet 1 [8642], Seite 799-803. [9] Walsh, P. C.; Partin, A. W. und Epstein, J. I. (1994): Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years, J Urol. 152 [5 Pt 2], Seite 1831-1836. [10] Deger, S.; Boehmer, D.; Turk, I.; Roigas, J.; Wernecke, K. D.; Wiegel, T.; Hinkelbein, W.; Dinges, S.; Budach, V. und Loening, S. A. (2002): High dose rate brachytherapy of localized prostate cancer, Eur.Urol. 41 [4], Seite 420-426. [11] Zincke, H.; Oesterling, J. E.; Blute, M. L.; Bergstralh, E. J.; Myers, R. P. und Barrett, D. M. (1994): Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer, J Urol. 152 [5 Pt 2], Seite 1850-1857. [12] Carlin, B. I. und Andriole, G. L. (2000): The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma, Cancer 88 [12 Suppl], Seite 2989-2994. [13] Whitmore, W. F., Jr. (1984): Natural history and staging of prostate cancer, Urol.Clin.North Am. 11 [2], Seite 205-220. [14] Nagase, H. und Woessner, J. F., Jr. (1999): Matrix metalloproteinases, J Biol.Chem. 274 [31], Seite 21491-21494. [15] Vihinen, P. und Kahari, V. M. (2002): Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets, Int.J Cancer 99 [2], Seite 157-166. [16] Barrett, A. J.; Rawlings, N. D. und Woessner, J. F., Jr. (1998): Handbook of Proteolytic Enzymes,

San Diego
, 0-12-079370-9. [17] Sterchi, E. E. und Stöcker, W. (1999): Proteolytic Enzymes - Tools and Targets, Seite 1-11, Springer- Verlag, 3-540-61233-5. [18] Hulboy, D. L.; Rudolph, L. A. und Matrisian, L. M. (1997): Matrix metalloproteinases as mediators of reproductive function, Mol.Hum.Reprod. 3 [1], Seite 27-45. [19] Bullard, K. M.; Lund, L.; Mudgett, J. S.; Mellin, T. N.; Hunt, T. K.; Murphy, B.; Ronan, J.; Werb, Z. und Banda, M. J. (1999): Impaired wound contraction in stromelysin-1-deficient mice, Ann.Surg. 230 [2], Seite 260-265. [20] Alexander, C. M.; Hansell, E. J.; Behrendtsen, O.; Flannery, M. L.; Kishnani, N. S.; Hawkes, S. P. und Werb, Z. (1996): Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation, Development 122 [6], Seite 1723-1736. [21] Gearing, A. J.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A. H.; Drummond, A. H.; Galloway, W. A.; Gilbert, R. und Gordon, J. L. (1994): Processing of tumour necrosis factor-alpha precursor by metalloproteinases, Nature 370 [6490], Seite 555-557. [22] Dubois, B.; Starckx, S.; Pagenstecher, A.; Oord, J.; Arnold, B. und Opdenakker, G. (2002): Gelatinase B deficiency protects against endotoxin shock, Eur.J Immunol 32 [8], Seite 2163-2171. [23] Kim, J.; Yu, W.; Kovalski, K. und Ossowski, L. (1998): Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay, Cell 94 [3], Seite 353-362. [24] Lochter, A.; Galosy, S.; Muschler, J.; Freedman, N.; Werb, Z. und Bissell, M. J. (1997): Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells, J Cell Biol. 139 [7], Seite 1861-1872. [25] Ala-Aho, R.; Johansson, N.; Baker, A. H. und Kahari, V. M. (2002): Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells, Int.J Cancer 97 [3], Seite 283-289. [26] Bernhard, E. J.; Gruber, S. B. und Muschel, R. J. (1994): Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells, Proc.Natl.Acad.Sci.U.S.A 91 [10], Seite 4293-4297. [27] Werb, Z. (1997): ECM and cell surface proteolysis: regulating cellular ecology, Cell 91 [4], Seite 439-442. [28] Johnson, L. L.; Pavlovsky, A. G.; Johnson, A. R.; Janowicz, J. A.; Man, C. F.; Ortwine, D. F.; Purchase, C. F.; White, A. D. und Hupe, D. J. (2000): A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition, J Biol.Chem. 275 [15], Seite 11026-11033. [29] Borkakoti, N. (1998): Matrix metalloproteases: variations on a theme, Prog.Biophys.Mol.Biol. 70 [1], Seite 7-94. [30] Van Wart, H. E. und Birkedal-Hansen, H. (1990): The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family, Proc.Natl.Acad.Sci.U.S.A 87 [14], Seite 5578-5582. [31] Sato, H.; Takino, T.; Okada, Y.; Cao, J.; Shinagawa, A.; Yamamoto, E. und Seiki, M. (1994): A matrix metalloproteinase expressed on the surface of invasive tumour cells, Nature 370 [6484], Seite 61-65. [32] Cox, G.; Steward, W. P. und O'Byrne, K. J. (1999): The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer, Thorax 54 [2], Seite 169-179. [33] Woolley, D. E.; Roberts, D. R. und Evanson, J. M. (1976): Small molecular weight beta 1 serum protein which specifically inhibits human collagenases, Nature 261 [5558], Seite 325-327. [34] Jiang, Y.; Goldberg, I. D. und Shi, Y. E. (2002): Complex roles of tissue inhibitors of metalloproteinases in cancer, Oncogene 21 [14], Seite 2245-2252. [35] Pavlaki, M. und Zucker, S. (2003): Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials, Cancer Metastasis Rev. 22 [2-3], Seite 177-203. [36] Nuovo, G. J.; MacConnell, P. B.; Simsir, A.; Valea, F. und French, D. L. (1995): Correlation of the in situ detection of polymerase chain reaction- amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma, Cancer Res. 55 [2], Seite 267-275. [37] Coussens, L. M. und Werb, Z. (1996): Matrix metalloproteinases and the development of cancer, Chem.Biol. 3 [11], Seite 895-904. [38] Goss, K. J.; Brown, P. D. und Matrisian, L. M. (1998): Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis, Int.J.Cancer 78 [5], Seite 629-635. [39] Gasson, J. C.; Golde, D. W.; Kaufman, S. E.; Westbrook, C. A.; Hewick, R. M.; Kaufman, R. J.; Wong, G. G.; Temple, P. A.; Leary, A. C.; Brown, E. L. und . (1985): Molecular characterization and expression of the gene encoding human erythroid-potentiating activity, Nature 315 [6022], Seite 768-771. [40] DeClerck, Y. A. und Imren, S. (1994): Protease inhibitors: role and potential therapeutic use in human cancer, Eur.J Cancer 30A [14], Seite 2170-2180. [41] Wilson, C. L.; Heppner, K. J.; Labosky, P. A.; Hogan, B. L. und Matrisian, L. M. (1997): Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin, Proc.Natl.Acad.Sci.U.S.A 94 [4], Seite 1402-1407. [42] Khokha, R. und Denhardt, D. T. (1989): Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion, Invasion Metastasis 9 [6], Seite 391-405. [43] Hashimoto, K.; Kihira, Y.; Matuo, Y. und Usui, T. (1998): Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate, J Urol. 160 [5], Seite 1872-1876. [44] Koop, S.; Khokha, R.; Schmidt, E. E.; MacDonald, I. C.; Morris, V. L.; Chambers, A. F. und Groom, A. C. (1994): Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth, Cancer Res. 54 [17], Seite 4791-4797. [45] Wojtowicz-Praga, S. M.; Dickson, R. B. und Hawkins, M. J. (1997): Matrix metalloproteinase inhibitors, Invest New Drugs 15 [1], Seite 61-75. [46] Grant, G. M.; Giambernardi, T. A.; Grant, A. M. und Klebe, R. J. (1999): Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells, Matrix Biol. 18 [2], Seite 145-148. [47] Greene, G. F.; Kitadai, Y.; Pettaway, C. A.; von Eschenbach, A. C.; Bucana, C. D. und Fidler, I. J. (1997): Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique, Am.J Pathol. 150 [5], Seite 1571-1582. [48] Wilson, M. J.; Sellers, R. G.; Wiehr, C.; Melamud, O.; Pei, D. und Peehl, D. M. (2002): Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells, J Cell Physiol 191 [2], Seite 208-216. [49] Zhang, J.; Jung, K.; Lein, M.; Kristiansen, G.; Rudolph, B.; Hauptmann, S.; Schnorr, D.; Loening, S. A. und Lichtinghagen, R. (2002): Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines, Prostate 50 [1], Seite 38-45. [50] Li, H.; Fang, W. und Zheng, J. (1998): [Zymographic analysis of MMPs in human carcinoma cell lines with different metastasis potential], Zhonghua Bing.Li Xue.Za Zhi. 27 [5], Seite 341-343. [51] Powell, W. C.; Fingleton, B.; Wilson, C. L.; Boothby, M. und Matrisian, L. M. (1999): The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis, Curr.Biol. 9 [24], Seite 1441-1447. [52] Sanchez-Sweatman, O. H.; Orr, F. W. und Singh, G. (2000): Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases [In Process Citation], Invasion Metastasis 18 [5-6], Seite 297-305. [53] Sternlicht, M. D.; Lochter, A.; Sympson, C. J.; Huey, B.; Rougier, J. P.; Gray, J. W.; Pinkel, D.; Bissell, M. J. und Werb, Z. (1999): The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis, Cell 98 [2], Seite 137-146. [54] Kolkhorst, V.; Sturzebecher, J. und Wiederanders, B. (1998): Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile, J.Cancer Res.Clin.Oncol. 124 [11], Seite 598-606. [55] Codony-Servat, J.; Albanell, J.; Lopez-Talavera, J. C.; Arribas, J. und Baselga, J. (1999): Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells, Cancer Res. 59 [6], Seite 1196-1201. [56] Dong, J.; Opresko, L. K.; Dempsey, P. J.; Lauffenburger, D. A.; Coffey, R. J. und Wiley, H. S. (1999): Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor, Proc.Natl.Acad.Sci U.S.A 96 [11], Seite 6235-6240. [57] Festuccia, C.; Bologna, M.; Vicentini, C.; Tacconelli, A.; Miano, R.; Violini, S. und Mackay, A. R. (1996): Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells, Int.J Cancer 69 [5], Seite 386-393. [58] Hamdy, F. C.; Fadlon, E. J.; Cottam, D.; Lawry, J.; Thurrell, W.; Silcocks, P. B.; Anderson, J. B.; Williams, J. L. und Rees, R. C. (1994): Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia, Br J Cancer 69 [1], Seite 177-182. [59] Knox, J. D.; Wolf, C.; McDaniel, K.; Clark, V.; Loriot, M.; Bowden, G. T. und Nagle, R. B. (1996): Matrilysin expression in human prostate carcinoma, Mol.Carcinog. 15 [1], Seite 57-63. [60] Stearns, M. und Stearns, M. E. (1996): Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression, Oncol.Res. 8 [2], Seite 69-75. [61] Stearns, M. E. und Stearns, M. (1996): Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer, Oncol.Res. 8 [2], Seite 63-67. [62] Still, K.; Robson, C. N.; Autzen, P.; Robinson, M. C. und Hamdy, F. C. (2000): Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue, Prostate 42 [1], Seite 18-25. [63] Wood, M.; Fudge, K.; Mohler, J. L.; Frost, A. R.; Garcia, F.; Wang, M. und Stearns, M. E. (1997): In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer, Clin.Exp.Metastasis 15 [3], Seite 246-258. [64] Festuccia, C.; Giunciuglio, D.; Guerra, F.; Villanova, I.; Angelucci, A.; Manduca, P.; Teti, A.; Albini, A. und Bologna, M. (1999): Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion, Oncol.Res. 11 [1], Seite 17-31. [65] Hiraoka, N.; Allen, E.; Apel, I. J.; Gyetko, M. R. und Weiss, S. J. (1998): Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins, Cell 95 [3], Seite 365-377. [66] Masson, R.; Lefebvre, O.; Noel, A.; Fahime, M. E.; Chenard, M. P.; Wendling, C.; Kebers, F.; LeMeur, M.; Dierich, A.; Foidart, J. M.; Basset, P. und Rio, M. C. (1998): In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy, J.Cell Biol. 140 [6], Seite 1535-1541. [67] McKerrow, J. H.; Bhargava, V.; Hansell, E.; Huling, S.; Kuwahara, T.; Matley, M.; Coussens, L. und Warren, R. (2000): A functional proteomics screen of proteases in colorectal carcinoma, Mol.Med. 6 [5], Seite 450-460. [68] Knox, J. D.; Bretton, L.; Lynch, T.; Bowden, G. T. und Nagle, R. B. (1998): Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model, Prostate 35 [4], Seite 248-254. [69] Hofmann, U. B.; Westphal, J. R.; Zendman, A. J.; Becker, J. C.; Ruiter, D. J. und van Muijen, G. N. (2000): Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression, J Pathol. 191 [3], Seite 245-256. [70] Zervos, E. E.; Shafii, A. E. und Rosemurgy, A. S. (1999): Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer, J.Surg.Res. 81 [1], Seite 65-68. [71] Lokeshwar, B. L. (1999): MMP inhibition in prostate cancer, Ann.N.Y.Acad.Sci. 878, Seite 271-289. [72] Nemeth, J. A.; Yousif, R.; Herzog, M.; Che, M.; Upadhyay, J.; Shekarriz, B.; Bhagat, S.; Mullins, C.; Fridman, R. und Cher, M. L. (2002): Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis, J Natl.Cancer Inst. 94 [1], Seite 17-25. [73] Sternlicht, M. D.; Bissell, M. J. und Werb, Z. (2000): The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter, Oncogene 19 [8], Seite 1102-1113. [74] Fingleton, B. M.; Heppner Goss, K. J.; Crawford, H. C. und Matrisian, L. M. (1999): Matrilysin in early stage intestinal tumorigenesis, APMIS 107 [1], Seite 102-110. [75] Cockett, M. I.; Murphy, G.; Birch, M. L.; O'Connell, J. P.; Crabbe, T.; Millican, A. T.; Hart, I. R. und Docherty, A. J. (1998): Matrix metalloproteinases and metastatic cancer, Biochem.Soc.Symp. 63, Seite 295-313. [76] Parsons, S. L.; Watson, S. A.; Collins, H. M.; Griffin, N. R.; Clarke, P. A. und Steele, R. J. (1998): Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy, Br.J.Cancer 78 [11], Seite 1495-1502. [77] Lein, M.; Nowak, L.; Jung, K.; Koenig, F.; Schnorr, D. und Loening, S. A. (1998): [Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma], Urologe A 37 [4], Seite 377-381. [78] Ahmad, A.; Hanby, A.; Dublin, E.; Poulsom, R.; Smith, P.; Barnes, D.; Rubens, R.; Anglard, P. und Hart, I. (1998): Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression, Am.J Pathol. 152 [3], Seite 721-728. [79] Reich, R.; Thompson, E. W.; Iwamoto, Y.; Martin, G. R.; Deason, J. R.; Fuller, G. C. und Miskin, R. (1988): Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells, Cancer Res. 48 [12], Seite 3307-3312. [80] Davies, B.; Brown, P. D.; East, N.; Crimmin, M. J. und Balkwill, F. R. (1993): A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts [published erratum appears in Cancer Res 1993 Aug 1;53(15):3652], Cancer Res. 53 [9], Seite 2087-2091. [81] Santos, O.; McDermott, C. D.; Daniels, R. G. und Appelt, K. (1997): Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases, Clin.Exp.Metastasis 15 [5], Seite 499-508. [82] Shalinsky, D. R.; Brekken, J.; Zou, H.; Bloom, L. A.; McDermott, C. D.; Zook, S.; Varki, N. M. und Appelt, K. (1999): Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies, Clin.Cancer Res. 5 [7], Seite 1905-1917. [83] Bu, W.; Tang, Z. Y.; Sun, F. X.; Ye, S. L.; Liu, K. D.; Xue, Q.; Chen, J. und Gao, D. M. (1998): Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20, Hepatogastroenterology. 45 [22], Seite 1056-1061. [84] Giavazzi, R.; Garofalo, A.; Ferri, C.; Lucchini, V.; Bone, E. A.; Chiari, S.; Brown, P. D.; Nicoletti, M. I. und Taraboletti, G. (1998): Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts, CLIN.CANC.RES. 4/4 [985-992]-992. [85] Zervos, E. E.; Norman, J. G.; Gower, W. R.; Franz, M. G. und Rosemurgy, A. S. (1997): Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo, J.Surg.Res. 69 [2], Seite 367-371. [86] Sledge-GW, Jr; Qulali, M.; Goulet, R.; Bone, E. A. und Fife, R. (1995): Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice, J.Natl.Cancer Inst. 87 [20], Seite 1546-1550. [87] Wang, X.; Fu, X.; Brown, P. D.; Crimmin, M. J. und Hoffman, R. M. (1994): Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice, Cancer Res. 54 [17], Seite 4726-4728. [88] Anderson, I. C.; Shipp, M. A.; Docherty, A. J. und Teicher, B. A. (1996): Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma, Cancer Res. 56 [4], Seite 715-718. [89] Macaulay, V. M.; O'Byrne, K. J.; Saunders, M. P.; Braybrooke, J. P.; Long, L.; Gleeson, F.; Mason, C. S.; Harris, A. L.; Brown, P. und Talbot, D. C. (1995): Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions., Br J Cancer 71(Suppl XXIV) [11(Abstr)]. [90] Beattie, G. J., Young, H. A., and Smyth, J. F.:Phase I study of intraperitoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites., 8th NCI-EORTC Symposium on New Drug Development, Amsterdam, March 1994. [91] Hidalgo, M. und Eckhardt, S. G. (2001): Development of matrix metalloproteinase inhibitors in cancer therapy, J Natl.Cancer Inst. 93 [3], Seite 178-193. [92] Rudek, M. A.; Figg, W. D.; Dyer, V.; Dahut, W.; Turner, M. L.; Steinberg, S. M.; Liewehr, D. J.; Kohler, D. R.; Pluda, J. M. und Reed, E. (2001): Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J.Clin.Oncol. 19 [2], Seite 584-592. [93] Bayer Pharmaceutical Division:Bayer Halts Clinical Trials Evaluating MMPI.URL: www.bayerpharma-na.com/news/co0221.asp [94] Brown, P. D. und Giavazzi, R. (1995): Matrix metalloproteinase inhibition: a review of anti-tumour activity, Ann.Oncol. 6 [10], Seite 967-974. [95] Yip, D.; Ahmad, A.; Karapetis, C. S.; Hawkins, C. A. und Harper, P. G. (1999): Matrix metalloproteinase inhibitors: applications in oncology, Invest New Drugs 17 [4], Seite 387-399. [96] Heath, E. I. und Grochow, L. B. (2000): Clinical potential of matrix metalloprotease inhibitors in cancer therapy, Drugs 59 [5], Seite 1043-1055. [97] Coussens, L. M.; Fingleton, B. und Matrisian, L. M. (2002): Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science 295 [5564], Seite 2387-2392. [98] Aparicio, T.; Kermorgant, S.; Dessirier, V.; Lewin, M. J. und Lehy, T. (1999): Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats, Carcinogenesis 20 [8], Seite 1445-1451. [99] Low, J. A.; Johnson, M. D.; Bone, E. A. und Dickson, R. B. (1996): The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice, Clin.Cancer Res. 2 [7], Seite 1207-1214. [100] Eccles, S. A.; Box, G. M.; Court, W. J.; Bone, E. A.; Thomas, W. und Brown, P. D. (1996): Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94), Cancer Res. 56 [12], Seite 2815-2822. [101] Watson, S. A.; Morris, T. M.; Robinson, G.; Crimmin, M. J.; Brown, P. D. und Hardcastle, J. D. (1995): Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models, Cancer Res. 55 [16], Seite 3629-3633. [102] Taraboletti, G.; Garofalo, A.; Belotti, D.; Drudis, T.; Borsotti, P.; Scanziani, E.; Brown, P. D. und Giavazzi, R. (1995): Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases, J.Natl.Cancer Inst. 87 [4], Seite 293-298. [103] Chirivi, R. G.; Garofalo, A.; Crimmin, M. J.; Bawden, L. J.; Stoppacciaro, A.; Brown, P. D. und Giavazzi, R. (1994): Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor, Int.J.Cancer 58 [3], Seite 460-464. [104] Jimenez, R. E.; Hartwig, W.; Antoniu, B. A.; Compton, C. C.; Warshaw, A. L. und Fernandez-Del Castillo, C. (2000): Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control, Ann.Surg. 231 [5], Seite 644-654. [105] Erba, E.; Ronzoni, S.; Bassano, L.; Giavazzi, R. und D'Incalci, M. (1999): The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells, Ann.Oncol. 10 [5], Seite 589-591. [106] Tonn, J. C.; Kerkau, S.; Hanke, A.; Bouterfa, H.; Mueller, J. G.; Wagner, S.; Vince, G. H. und Roosen, K. (1999): Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro, Int.J.Cancer 80 [5], Seite 764-772. [107] Stonelake, P. S.; Jones, C. E.; Neoptolemos, J. P. und Baker, P. R. (1997): Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines, Br.J.Cancer 75 [7], Seite 951-959. [108] Parvathy, S.; Oppong, S. Y.; Karran, E. H.; Buckle, D. R.; Turner, A. J. und Hooper, N. M. (1997): Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer, Biochem.J. 327 ( Pt 1), Seite 37-43. [109] Beattie, G. J. und Smyth, J. F. (1998): Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites, Clin.Cancer Res. 4 [8], Seite 1899-1902. [110] Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M. und Fielding, J. W. (2002): Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial, Br J Cancer 86 [12], Seite 1864-1870. [111] Lokeshwar, B. L.; Selzer, M. G.; Zhu, B. Q.; Block, N. L. und Golub, L. M. (2002): Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model, Int.J Cancer 98 [2], Seite 297-309. [112] Saad, F. Klotz L. Babaian R. Lacombe L. Champagne P. andDupont É.:Phase I/II trial on Æ-941 (Neovastat) in patients with metastatic refractory prostate cancer..URL: www.aeterna.com/aeterna/ang/search/search.asp?P=1&str=prostate [113] Wilding, G., Small, E, and Collier, M. (15-5-1999):A phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer
Atlanta, GA
.URL: www.conference-cast.com/asco/abstract_frame.htm [114] Boasberg, P., Harbaugh, Eisenberger, M., Harris, J, Langleben, A., Ahmann, F., Roth.B., Berkheimer, M., and Rasmussen, H.:Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. (Abstr. No. 1126).URL: www.conference-cast.com/asco/abstract_frame.htm [115] Eisenberger, M., Sinibaldi, V., Laufer, M., Carducci, M., Miller, C., Boasberg, P., Ahmann, F., and Roth.B. (2000):Phase-I/+ Pharmacokinetic Evaluation of Marimastat in Patients (PTS) with Advanced Prostate Cancer (PC): Identificataion of the Biologically Acitve Dose. (19). [116] Stone, K. R.; Mickey, D. D.; Wunderli, H.; Mickey, G. H. und Paulson, D. F. (1978): Isolation of a human prostate carcinoma cell line (DU 145), Int.J Cancer 21 [3], Seite 274-281. [117] Horoszewicz, J. S; Leong, S S.; Chu, T. M.; Wajsman, Z. L.; Friedman, M.; Papsidero, L.; Kim, U.; Chai, L. S.; Kakati, S.; Arya, S. k. und Sandberg, A. A. (1980): The LNCaP Cell Line - A New Model for Studies on Human Prostatic Carcinoma, Murphy, G. P., Models for Prostate Cancer , Seite 115-132,
New York
. [118] Kaighn, M. E.; Lechner, J. F.; Babcock, M. S.; Marnell, M.; Ohnuki, Y. und Narayan, K. S. (1980): The Pasadena Cell Lines, Murphy, G. P., Models for prostate Cancer , Seite 85-109,
New York
. [119] Lubaroff, D. M.; Canfield, L. und Reynolds, C. W. (1980): The Dunning Tumors, Murphy, G. P., Models for Prostate Cancer , Seite 243-263,
New York
. [120] Lucia, M. S.; Bostwick, D. G.; Bosland, M.; Cockett, A. T.; Knapp, D. W.; Leav, I.; Pollard, M.; Rinker, Schaeffer C.; Shirai, T. und Watkins, B. A. (1998): Workgroup I: rodent models of prostate cancer, Prostate 36 [1], Seite 49-55. [121] Wikstrom, P.; Lindh, G.; Bergh, A. und Damber, J. E. (1999): Alterations of transforming growth factor beta1 (TGF-beta1) and TGFbeta receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines, Urol.Res. 27 [3], Seite 185-193. [122] Blount, L. V. und Cooke, D. B., III (1996): Point mutations in the Ki-ras2 gene of codon 12 in the Dunning R-3327 Prostatic Adenocarcinoma system, Prostate 28 [1], Seite 44-50. [123] Rao, B. R.; Slotman, B. J.; Geldof, A. A. und Perez, C. A. (1991): Radiation sensitivity of Copenhagen rat prostatic carcinoma (R3327-AT and R3327-MATLyLu), Int.J.Radiat.Oncol.Biol.Phys. 20 [5], Seite 981-985. [124] Smolev, J. K.; Heston, W. D.; Scott, W. W. und Coffey, D. S. (1977): Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer, Cancer Treat.Rep. 61 [2], Seite 273-287. [125] Tennant, T. R.; Kim, H.; Sokoloff, M. und Rinker-Schaeffer, C. W. (2000): The Dunning model, Prostate 43 [4], Seite 295-302. [126] Garde, S. V.; Sheth, A. R.; Porter, A. T. und Pienta, K. J. (1993): A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines, Cancer Lett. 70 [3], Seite 159-166. [127] Isaacs, J. T. (1996): The R-3327 System of Rat Prostatic Cancers, Urologic Oncology 2 [4], Seite 115-116. [128] Isaacs, J. T.; Yu, G. W. und Coffey, D. S. (1981): The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor, Invest Urol. 19 [1], Seite 20-23. [129] Haggstrom, S.; Wikstrom, P.; Bergh, A. und Damber, J. E. (1998): Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration, Prostate 36 [2], Seite 71-79. [130] Steiner, M. S.; Zhou, Z. Z.; Tonb, D. C. und Barrack, E. R. (1994): Expression of transforming growth factor-beta 1 in prostate cancer, Endocrinology 135 [5], Seite 2240-2247. [131] Isaacs, J. T.; Isaacs, W. B.; Feitz, W. F. und Scheres, J. (1986): Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers, Prostate 9 [3], Seite 261-281. [132] Berridge, M. V.; Tan, A. S.; McCoy, K. D. und Wang, R. (1996): The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts, Biochemica 4, Seite 14-19. [133] Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro, Wolff A. und et, al (1991): Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines, J.Natl.Cancer Inst. 83 [11], Seite 757-766. [134] Plumb, J. A.; Milroy, R. und Kaye, S. B. (1989): Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay, Cancer Res. 49 [16], Seite 4435-4440. [135] Romijn, J. C.; Verkoelen, C. F. und Schroeder, F. H. (1988): Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects, Prostate 12 [1], Seite 99-110. [136] Berridge, M. V. und Tan, A. S. (1993): Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction, Arch.Biochem.Biophys. 303 [2], Seite 474-482. [137] Skehan, P. (1998): Cytotoxicity and Cell Growth Assays, Celis, J. E., Cell Biology , Seite 313-318, 0-12-164726-9. [138] Bank, U.; Reinhold, D. und Ansorge, S. (1991): Messung der zellulären Aktivität mit Hilfe des MTT-Farbtests, Allerg Immunol 37, Seite 119-123. [139] Sieuwerts, A. M.; Klijn, J. G.; Peters, H. A. und Foekens, J. A. (1995): The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival, Eur.J.Clin.Chem.Clin.Biochem. 33 [11], Seite 813-823. [140] Freshney, R. I. (2000): Measurement of Viability and Cytotoxicity, Freshney, R. I., Culture of animal cells , 3. Auflage, Seite 287-307. [141] Holst-Hansen, C. und Brunner, N. (1998): MTT-Cell Proliferation Assay, Celis, J. E., Cell Biology , 2. Auflage, Seite 16-18, 0-12-164726-9. [142] Ravenna, L.; Lubrano, C.; Di, Silverio F.; Vacca, A.; Felli, M. P.; Maroder, M.; D'Eramo, G.; Sciarra, F.; Frati, L.; Gulino, A. und et, al (1995): Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP, Prostate 26 [6], Seite 290-298. [143] Watson, S. A.; Morris, T. M.; Parsons, S. L.; Steele, R. J. und Brown, P. D. (1996): Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model, Br.J.Cancer 74 [9], Seite 1354-1358. [144] Hanglow, A. C.; Lugo, A.; Walsky, R.; Finch-Arietta, M.; Lusch, L.; Visnick, M. und Fotouhi, N. (1993): Peptides based on the conserved predomain sequence of matrix metalloproteinases inhibit human stromelysin and collagenase, Agents Actions 39 Spec No, Seite C148-C150. [145] Jung, K.; Nowak, L.; Lein, M.; Priem, F.; Schnorr, D. und Loening, S. A. (1997): Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer, Int.J Cancer 74 [2], Seite 220-223. [146] Baker, T.; Tickle, S.; Wasan, H.; Docherty, A.; Isenberg, D. und Waxman, J. (1994): Serum metalloproteinases and their inhibitors: markers for malignant potential, Br J Cancer 70 [3], Seite 506-512. [147] Boasberg, P., Harbaugh, B., Roth, B., Eisenberger, M., Langleben, A., Allen, R., and Rasmussen, H.:Marimastat, a novel matrix metalloproteinse inhibitor in patients with hormone-refractory prostate cancer (15).URL: www.asco.org/ac/1,1003,_12-002489-00_18-001996-00_19-009282-00_28-00RESULTPAGE,00.asp [148] Shaffer, D. R. und Scher, H. I. (2003): Prostate cancer: a dynamic illness with shifting targets, Lancet Oncol. 4 [7], Seite 407-414. [149] Matsuura, E.; Umehara, F.; Hashiguchi, T.; Fujimoto, N.; Okada, Y. und Osame, M. (2000): Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis, J Neurol.Sci. 173 [1], Seite 45-52. [150] Zucker, S.; Hymowitz, M.; Conner, C.; Zarrabi, H. M.; Hurewitz, A. N.; Matrisian, L.; Boyd, D.; Nicolson, G. und Montana, S. (1999): Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications, Ann.N.Y.Acad.Sci. 878, Seite 212-227. [151] Jiang, Y.; Wang, M.; Celiker, M. Y.; Liu, Y. E.; Sang, Q. X.; Goldberg, I. D. und Shi, Y. E. (2001): Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery, Cancer Res. 61 [6], Seite 2365-2370. [152] Hanemaaijer, R.; Verheijen, J. H.; Maguire, T. M.; Visser, H.; Toet, K.; McDermott, E.; O'Higgins, N. und Duffy, M. J. (2000): Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors, Int.J Cancer 86 [2], Seite 204-207. [153] Kuniyasu, H.; Troncoso, P.; Johnston, D.; Bucana, C. D.; Tahara, E.; Fidler, I. J. und Pettaway, C. A. (2000): Relative expression of type IV collagenae, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers [In Process Citation], Clin.Cancer Res. 6 [6], Seite 2295-2308. [154] Nakanishi, K.; Kawai, T.; Sato, H.; Aida, S.; Kasamatsu, H.; Aurues, T. und Ikeda, T. (2000): Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1-matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract, Hum.Pathol. 31 [2], Seite 193-200. [155] Maatta, M.; Soini, Y.; Liakka, A. und Autio-Harmainen, H. (2000): Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis, Clin.Cancer Res. 6 [7], Seite 2726-2734. [156] Upadhyay, J.; Shekarriz, B.; Nemeth, J. A.; Dong, Z.; Cummings, G. D.; Fridman, R.; Sakr, W.; Grignon, D. J. und Cher, M. L. (1999): Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia, Clin.Cancer Res. 5 [12], Seite 4105-4110. [157] Vaisanen, A.; Kallioinen, M.; Taskinen, P. J. und Turpeenniemi, Hujanen T. (1998): Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma, J.Pathol. 186 [1], Seite 51-58. [158] Bando, E.; Yonemura, Y.; Endou, Y.; Sasaki, T.; Taniguchi, K.; Fujita, H.; Fushida, S.; Fujimura, T.; Nishimura, G.; Miwa, K. und Seiki, M. (1998): Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis, Oncol.Rep. 5 [6], Seite 1483-1488. [159] Etoh, T.; Inoue, H.; Yoshikawa, Y.; Barnard, G. F.; Kitano, S. und Mori, M. (2000): Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness, Gut 47 [1], Seite 50-56. [160] Moser, P. L.; Kieback, D. G.; Hefler, L.; Tempfer, C.; Neunteufel, W. und Gitsch, G. (1999): Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer, Anticancer Res. 19 [5C], Seite 4391-4393. [161] Yamashita, K.; Tanaka, Y.; Mimori, K.; Inoue, H. und Mori, M. (2004): Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma, Int.J Cancer 110 [2], Seite 201-207. [162] Chenard, M. P.; O'Siorain, L.; Shering, S.; Rouyer, N.; Lutz, Y.; Wolf, C.; Basset, P.; Bellocq, J. P. und Duffy, M. J. (1996): High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma, Int.J Cancer 69 [6], Seite 448-451. [163] Jones, J. L.; Glynn, P. und Walker, R. A. (1999): Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas, J Pathol. 189 [2], Seite 161-168. [164] Powe, D. G.; Brough, J. L.; Carter, G. I.; Bailey, E. M.; Stetler-Stevenson, W. G.; Turner, D. R. und Hewitt, R. E. (1997): TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma, Br J Cancer 75 [11], Seite 1678-1683. [165] Joo, Y. E.; Seo, K. S.; Kim, H. S.; Rew, J. S.; Park, C. S. und Kim, S. J. (2000): Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer, Dig.Dis.Sci 45 [1], Seite 114-121. [166] Michael, M.; Babic, B.; Khokha, R.; Tsao, M.; Ho, J.; Pintilie, M.; Leco, K.; Chamberlain, D. und Shepherd, F. A. (1999): Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer, J Clin.Oncol. 17 [6], Seite 1802-1808. [167] Kossakowska, A. E.; Urbanski, S. J. und Edwards, D. R. (1991): Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas, Blood 77 [11], Seite 2475-2481. [168] McCarthy, K.; Maguire, T.; McGreal, G.; McDermott, E.; O'Higgins, N. und Duffy, M. J. (1999): High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer, Int.J Cancer 84 [1], Seite 44-48. [169] Zeng, Z. S.; Cohen, A. M.; Zhang, Z. F.; Stetler-Stevenson, W. und Guillem, J. G. (1995): Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases, Clin.Cancer Res. 1 [8], Seite 899-906. [170] Holten-Andersen, M. N.; Stephens, R. W.; Nielsen, H. J.; Murphy, G.; Christensen, I. J.; Stetler-Stevenson, W. und Brunner, N. (2000): High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, Clin.Cancer Res. 6 [11], Seite 4292-4299. [171] Ylisirnio, S.; Hoyhtya, M. und Turpeenniemi-Hujanen, T. (2000): Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker, Anticancer Res. 20 [2B], Seite 1311-1316. [172] Davidson, B.; Goldberg, I.; Kopolovic, J.; Lerner-Geva, L.; Gotlieb, W. H.; Ben Baruch, G. und Reich, R. (1999): MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization, Gynecol.Oncol. 73 [3], Seite 372-382. [173] Tutton, M. G.; George, M. L.; Eccles, S. A.; Burton, S.; Swift, R. I. und Abulafi, A. M. (2003): Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients, Int.J Cancer 107 [4], Seite 541-550. [174] Lein, M.; Jung, K.; Laube, C.; Hubner, T.; Winkelmann, B.; Stephan, C.; Hauptmann, S.; Rudolph, B.; Schnorr, D. und Loening, S. A. (2000): Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma, Int.J Cancer 85 [6], Seite 801-804. [175] Giannelli, G.; Erriquez, R.; Fransvea, E.; Daniele, A.; Trerotoli, P.; Schittulli, F.; Grano, M.; Quaranta, M. und Antonaci, S. (2004): Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients, Int.J Cancer 109 [5], Seite 782-785. [176] Rudolph-Owen, L. A.; Chan, R.; Muller, W. J. und Matrisian, L. M. (1998): The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis, Cancer Res. 58 [23], Seite 5500-5506. [177] Witty, J. P.; Wright, J. H. und Matrisian, L. M. (1995): Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development, Mol.Biol.Cell 6 [10], Seite 1287-1303. [178] Albini, A.; Melchiori, A.; Santi, L.; Liotta, L. A.; Brown, P. D. und Stetler, Stevenson WG (1991): Tumor cell invasion inhibited by TIMP-2 [see comments], J.Natl.Cancer Inst. 83 [11], Seite 775-779. [179] Baker, A. H.; George, S. J.; Zaltsman, A. B.; Murphy, G. und Newby, A. C. (1999): Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3, Br.J.Cancer 79 [9-10], Seite 1347-1355. [180] Buck, T. B.; Yoshiji, H.; Harris, S. R.; Bunce, O. R. und Thorgeirsson, U. P. (1999): The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice, Ann.N Y.Acad.Sci 878, Seite 732-735. [181] Guedez, L.; McMarlin, A. J.; Kingma, D. W.; Bennett, T. A.; Stetler-Stevenson, M. und Stetler-Stevenson, W. G. (2001): Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis, Am.J Pathol. 158 [4], Seite 1207-1215. [182] Yoshiji, H.; Buck, T. B.; Harris, S. R.; Ritter, L. M.; Lindsay, C. K. und Thorgeirsson, U. P. (1998): Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinoma cells, Biochem.Biophys.Res.Commun. 247 [3], Seite 605-609. [183] Gross, J. und Lapiere, C. M. (1962): Collagenolytic Activity in Amphibian Tissues: A Tissue Culture Assay, Proc.Natl.Acad.Sci.U.S.A 48, Seite 1014-1022. [184] Cheng, L.; Mantile, G.; Pauly, R.; Nater, C.; Felici, A.; Monticone, R.; Bilato, C.; Gluzband, Y. A.; Crow, M. T.; Stetler, Stevenson W. und Capogrossi, M. C. (1998): Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo, Circulation 98 [20], Seite 2195-2201. [185] Melchiori, A.; Albini, A.; Ray, J. M. und Stetler-Stevenson, W. G. (1992): Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment, Cancer Res. 52 [8], Seite 2353-2356. [186] Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H. und Itohara, S. (1998): Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res. 58 [5], Seite 1048-1051. [187] Nabeshima, K.; Inoue, T.; Shimao, Y.; Kataoka, H. und Koono, M. (1999): Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets, Histol.Histopathol. 14 [4], Seite 1183-1197. [188] Nabeshima, K.; Inoue, T.; Shimao, Y.; Okada, Y.; Itoh, Y.; Seiki, M. und Koono, M. (2000): Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor, Cancer Res. 60 [13], Seite 3364-3369. [189] Legrand, C.; Gilles, C.; Zahm, J. M.; Polette, M.; Buisson, A. C.; Kaplan, H.; Birembaut, P. und Tournier, J. M. (1999): Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling, J Cell Biol. 146 [2], Seite 517-529. [190] Moses, M. A. (1997): The regulation of neovascularization of matrix metalloproteinases and their inhibitors, Stem.Cells 15 [3], Seite 180-189. [191] Yu, Q. und Stamenkovic, I. (2000): Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev. 14 [2], Seite 163-176. [192] Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z. und Hanahan, D. (2000): Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat.Cell Biol. 2 [10], Seite 737-744. [193] Cornelius, L. A.; Nehring, L. C.; Harding, E.; Bolanowski, M.; Welgus, H. G.; Kobayashi, D. K.; Pierce, R. A. und Shapiro, S. D. (1998): Matrix metalloproteinases generate angiostatin: effects on neovascularization, J.Immunol. 161 [12], Seite 6845-6852. [194] Fernandez, H. A.; Kallenbach, K.; Seghezzi, G.; Grossi, E.; Colvin, S.; Schneider, R.; Mignatti, P. und Galloway, A. (1999): Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1, J Surg.Res. 82 [2], Seite 156-162. [195] Murphy, A. N.; Unsworth, E. J. und Stetler-Stevenson, W. G. (1993): Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation, J Cell Physiol 157 [2], Seite 351-358. [196] Anand-Apte, B.; Pepper, M. S.; Voest, E.; Montesano, R.; Olsen, B.; Murphy, G.; Apte, S. S. und Zetter, B. (1997): Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3, Invest Ophthalmol.Vis.Sci 38 [5], Seite 817-823. [197] Yoshiji, H.; Harris, S. R.; Raso, E.; Gomez, D. E.; Lindsay, C. K.; Shibuya, M.; Sinha, C. C. und Thorgeirsson, U. P. (1998): Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression, Int.J Cancer 75 [1], Seite 81-87. [198] Yamada, E.; Tobe, T.; Yamada, H.; Okamoto, N.; Zack, D. J.; Werb, Z.; Soloway, P. D. und Campochiaro, P. A. (2001): TIMP-1 promotes VEGF-induced neovascularization in the retina, Histol.Histopathol. 16 [1], Seite 87-97. [199] Newell, K. J.; Matrisian, L. M. und Driman, D. K. (2002): Matrilysin (matrix metalloproteinase-7) expression in ulcerative colitis-related tumorigenesis, Mol.Carcinog. 34 [2], Seite 59-63. [200] Yamamoto, H.; Iku, S.; Adachi, Y.; Imsumran, A.; Taniguchi, H.; Nosho, K.; Min, Y.; Horiuchi, S.; Yoshida, M.; Itoh, F. und Imai, K. (2003): Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer, J Pathol. 199 [2], Seite 176-184. [201] Baker, E. A. und Leaper, D. J. (2003): The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology, Eur.J Cancer 39 [7], Seite 981-988. [202] Murray, G. I.; Duncan, M. E.; O'Neil, P.; Melvin, W. T. und Fothergill, J. E. (1996): Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer, Nat.Med 2 [4], Seite 461-462. [203] Davidson, B.; Goldberg, I.; Kopolovic, J.; Lerner-Geva, L.; Gotlieb, W. H.; Weis, B.; Ben Baruch, G. und Reich, R. (1999): Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization, Gynecol.Oncol. 72 [3], Seite 380-386. [204] Sheu, B. C.; Hsu, S. M.; Ho, H. N.; Lien, H. C.; Huang, S. C. und Lin, R. H. (2001): A novel role of metalloproteinase in cancer-mediated immunosuppression, Cancer Res. 61 [1], Seite 237-242. [205] Sheu, B. C.; Lien, H. C.; Ho, H. N.; Lin, H. H.; Chow, S. N.; Huang, S. C. und Hsu, S. M. (2003): Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer, Cancer Res. 63 [19], Seite 6537-6542. [206] Martignetti, J. A.; Aqeel, A. A.; Sewairi, W. A.; Boumah, C. E.; Kambouris, M.; Mayouf, S. A.; Sheth, K. V.; Eid, W. A.; Dowling, O.; Harris, J.; Glucksman, M. J.; Bahabri, S.; Meyer, B. F. und Desnick, R. J. (2001): Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome, Nat.Genet. 28 [3], Seite 261-265. [207] Trudel, D.; Fradet, Y.; Meyer, F.; Harel, F. und Tetu, B. (2003): Significance of MMP-2 expression in prostate cancer: an immunohistochemical study, Cancer Res. 63 [23], Seite 8511-8515. [208] Lichtinghagen, R.; Musholt, P. B.; Stephan, C.; Lein, M.; Kristiansen, G.; Hauptmann, S.; Rudolph, B.; Schnorr, D.; Loening, S. A. und Jung, K. (2003): mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue, Anticancer Res. 23 [3B], Seite 2617-2624. [209] Jung, K.; Krell, H. W.; Ortel, B.; Hasan, T.; Romer, A.; Schnorr, D.; Loening, S. A. und Lein, M. (2003): Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats, Prostate 54 [3], Seite 206-211.